OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Flow Eighteen38 Receives €5 Million (US$5.58 Million) to Expand Production and Biophysical Capabilities
Flow Eighteeen38 is receiving a €5 million (US$5.58 million) investment from its parent company, FairJourney Biologics.
Flow Eighteen38, a protein sciences company, announced a €5 Million (US$5.58 million)investment into its protein production and biophysical characterization capabilities on March 8, 2022. The investment comes from its parent company, FairJourney Biologics, a company specializing in the discovery and optimization of antibodies.
According to a company press release, the investment will be used to develop a new laboratory that will be designed to double the company's protein purification capacity. These facilities will accommodate 15+ high-end fast protein liquid chromatography systems, all of which will be individually optimized to scale-up custom production, support unique partner requirements, and fast-track standard productions.
The investment will also be used to purchase:
- LabChip’s GX Touch for capillary electrophoresis sodium dodecyl sulfate (CE-SDS)
- Thermo Scientific’s Vanquish ultra high-performance liquid chromatography (UHPLC)
- Endosafe nexgen-MCS for endotoxin testing
- Two BioAccord liquid chromatography–mass spectrometry (LC–MS) systems.
The funding will also drive further recruitment for production and characterization services and cold storage and logistics solutions. It will also contribute to continued supply of quality antibody reagents that comply with new European Union recommendations.
“This investment is further commitment to our partners to ensure we remain on the cutting-edge of protein production and biophysical solutions and to continue to deliver quality results our diverse portfolio of partners have come to know and expect,” said António Parada, CEO, FairJourney Biologics, in the press release.
“We are thrilled for this new stage of Flow Eighteen38,” said Teresa Barata, head of Protein Science Division, Flow Eighteen38, in the press release. “The new investment will enable us to continue to support our clients at the various stages of the discovery process and extend it to pre-[chemistry, manufacturing, and controls] stages, for faster and successful biotherapeutics development.”
Source: Flow Eighteen38